Michael MBA - Aeglea Bio Chief Officer
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
Insider
Michael MBA is Chief Officer of Aeglea Bio Therapeutics
| Age | 50 |
| Phone | 512 942 2935 |
| Web | https://www.aeglea.com |
Aeglea Bio Management Efficiency
The company has return on total asset (ROA) of (0.4182) % which means that it has lost $0.4182 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8141) %, meaning that it created substantial loss on money invested by shareholders. Aeglea Bio's management efficiency ratios could be used to measure how well Aeglea Bio manages its routine affairs as well as how well it operates its assets and liabilities.Aeglea Bio Therapeutics currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Aeglea Bio Therapeutics has a current ratio of 4.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aeglea Bio's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Susan Kahlert | Senti Biosciences | N/A | |
| Bronson Crouch | Instil Bio | 51 | |
| James Collins | Senti Biosciences | 58 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| Craig Lewis | Benitec Biopharma Ltd | N/A | |
| Robert Bazemore | Nuvation Bio | 53 | |
| David MD | Nuvation Bio | 54 | |
| Mark Dudley | Instil Bio | N/A | |
| BCPS PharmD | Xilio Development | 47 | |
| Stacey Davis | Xilio Development | N/A | |
| Thomas Walker | Bio Path Holdings | N/A | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| W Vernon | Nuvation Bio | 65 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| Philip Lee | Senti Biosciences | 42 | |
| Nicole White | Assembly Biosciences | N/A | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| Kathryn Falberg | Nuvation Bio | 60 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| James JD | Eliem Therapeutics | 58 | |
Management Performance
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 |
Aeglea Bio Therapeutics Leadership Team
Elected by the shareholders, the Aeglea Bio's board of directors comprises two types of representatives: Aeglea Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aeglea. The board's role is to monitor Aeglea Bio's management team and ensure that shareholders' interests are well served. Aeglea Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aeglea Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James JD, Pres CEO | ||
| Jonathan MBA, CFO Officer | ||
| Michael MBA, Chief Officer | ||
| Josie Gayton, Operations Strategy | ||
| Cortney MBA, VP Operations | ||
| Leslie Sloan, Chief Officer | ||
| Kelly Boothe, Sr Relations | ||
| Jeffrey Goldberg, CEO Pres | ||
| Joey Perrone, Director- Finance, IR Contact Officer | ||
| Scott Rowlinson, Vice President - Research | ||
| MBA MD, Chief Officer |
Aeglea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aeglea Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (94.85) % | |||
| Current Valuation | 228.21 M | |||
| Shares Outstanding | 4.05 M | |||
| Shares Owned By Insiders | 2.40 % | |||
| Shares Owned By Institutions | 97.60 % | |||
| Number Of Shares Shorted | 128.62 K | |||
| Price To Earning | (2.41) X | |||
| Price To Book | 0.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |